2-(p-Toluyl)-5-hydroxy-benzofuran | 41967-46-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(p-Toluyl)-5-hydroxy-benzofuran
• 英文别名: (5-Hydroxy-1-benzofuran-2-yl)-(4-methylphenyl)methanone
• CAS: 41967-46-8
• 化学式: C₁₆H₁₂O₃
• 分子量: 252.269
• InChiKey: JJCWOVSNGHTVKG-UHFFFAOYSA-N

物化性质

• 沸点：
  449.6±30.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
  申请人：Cheng Fei Jie

  公开号：US20050026969A1

  公开（公告）日：2005-02-03

  The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.

  本发明提供了一种结构如式I所示的化合物作为用途，含有该化合物的药物组合物，以及用于预防、管理和治疗代谢性疾病以及通过MCD抑制调节的疾病的方法。本发明公开的化合物可用于预防、管理和治疗涉及丙二酸调节的葡萄糖/脂肪酸代谢途径的疾病。特别是，这些化合物和含有相同化合物的药物组合物用于预防、管理和治疗心血管疾病、糖尿病、癌症和肥胖症。
• HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1653944B1

  公开（公告）日：2010-11-10
• JP2007501232A
  申请人：——

  公开号：JP2007501232A

  公开（公告）日：2007-01-25
• マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用な複素環式化合物
  申请人：中外製薬株式会社

  公开号：JP4727578B2

  公开（公告）日：2007-01-25
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS<br/>[FR] COMPOSES HETEROCYCLIQUES UTILES COMME INHIBITEURS DE LA MALONYL-COA DECARBOXYLASE
  申请人：CHUGAI PHARMACEUTICAL CO LTD

  公开号：WO2005011670A1

  公开（公告）日：2005-02-10

  The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.